Drug Profile
CLX 1100
Latest Information Update: 29 Jan 2003
Price :
$50
*
At a glance
- Originator Calyx Therapeutics (CEASED)
- Class Antirheumatics; Small molecules
- Mechanism of Action Interleukin 1 beta inhibitors; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 29 Jan 2003 Discontinued - Preclinical for Rheumatoid arthritis in USA (unspecified route)
- 23 Aug 2000 New profile
- 23 Aug 2000 Preclinical development for Rheumatoid arthritis in USA (Unknown route)